Loading...

ASPIRA WOMEN'S HEALTH INC Delisting Actions 8-K Filing

SPR

ASPIRA WOMEN'S HEALTH INC

()

2024 8-K

Laboratory Agreement

Loan Agreement Signed

Investor Presentation Update

Stock Purchase Agreement

Laboratory Services Agreement

Financial Results Report

Warrant Amendments

Convertible Notes Update

Private Placement Deal

Management Change

Regulatory Compliance

Nasdaq Delisting

Equity Agreement

Bylaw Amendment

CEO Appointment

Financial Results

Management Change

Director Resignation

Nasdaq Delisting

Management Changes

Management Changes

Investor Presentation

Management Changes

Nasdaq Delisting Notice

Financial Results

Product Pipeline Update

Funding Announcement

Funding Announcement

Investor Presentation

Financial Results

Agreement for Stock Sale

Warrant Inducement Agreement

Appointment of Director

Private Placement

Departure of CFO

Appointment and Salary Incr...

Earnings Reports

Annual Meeting Results

Earnings Report

Amendment to Employment Agr...

Appointment of President

Securities Purchase Agreement

Securities Purchase Agreement

Management Changes

Earnings Reports

Establishment of Clinical A...

Restatement of Financial St...

Compliance regained with Na...

Resignation of Officer

Earnings Reports

Resignation of Officer

Equity Offerings

Rights Offerings

Loan Forgiveness and Paymen...

Appointment of Director and...

Appointment of CFO

Reverse Stock Split

Earnings Report

Annual Meeting Voting Results

Earnings Reports

External Links:

Aspira Women’s Health Inc. received notice from Nasdaq that it failed to meet the $35 million market value requirement for continued listing, and it has until January 7, 2025, to appeal the delisting decision.

AI Assistant

ASPIRA WOMEN'S HEALTH INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.